Background: Diagnostic test accuracy (DTA) systematic reviews (SRs) characterize a test's potential for diagnostic quality and safety. However, interpreting DTA measures in the context of SRs is challenging. Further, some evidence grading methods (e.g. Centers for Disease Control and Prevention, Division of Laboratory Systems Laboratory Medicine Best Practices method) require determination of qualitative effect size ratings as a contributor to practice recommendations. This paper describes a recently developed effect size rating approach for assessing a DTA evidence base. Methods: A likelihood ratio scatter matrix will plot positive and negative likelihood ratio pairings for DTA studies. Pairings are graphed as single point estimates with confidence intervals, positioned in one of four quadrants derived from established thresholds for test clinical validity. These quadrants support defensible judgments on "substantial", "moderate", or "minimal" effect size ratings for each plotted study. The approach is flexible in relation to a priori determinations of the relative clinical importance of false positive and false negative test results. Results and conclusions: This qualitative effect size rating approach was operationalized in a recent SR that assessed effectiveness of test practices for the diagnosis of Clostridium difficile. Relevance of this approach to other methods of grading evidence, and efforts to measure diagnostic quality and safety are described. Limitations of the approach arise
Introduction Background
Clinical laboratory testing generates information to benefit patient management decisions in support of health, while inaccurate or inappropriate testing may contribute to patient harm [1] [2] [3] . Moreover, measures of diagnostic test accuracy (DTA) provide insight into a test's (or test combination's) ability to contribute to quality and safety within diagnostic pathways by estimating a test's clinical validity [4] . Based on rates of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FNs), these measures can inform the appropriate role of a test in a diagnostic pathway, and can assist in interpretation of test results for individual patients as generally depicted in Figure 1 [6] [7] [8] [9] .
Measures of DTA can be determined through diagnostic cross-sectional studies and diagnostic case-control studies which assess performance of one or more index tests in relation to a gold standard or reference method test [10] [11] [12] [13] . Through these study designs, rates of TP, FP, TN and FN are derived for assembly into various summary measures as illustrated in Figure 2 [14] .
DTA systematic reviews (SRs) are a method for developing recommendations on the use of a test or a combination of tests [15] [16] [17] . In DTA SRs, studies are synthesized to obtain pooled, and potentially more reliable, DTA measures. Further, DTA SRs may help investigators determine how DTA may vary by populations, settings/clinical contexts, or positivity thresholds [15, 16, 18, 19] . However, such findings are not the only arbiter of decisions on test implementation and interpretation in support of diagnostic quality and safety [20] [21] [22] . For example, a DTA evidence base, of itself, cannot directly indicate downstream consequences without additional linkage to separate bodies of evidence (e.g. on treatment efficacy for the target condition), or through logical inference [23] . Adding to the interpretative challenges, published DTA SRs often provide a scattershot of DTA measures, without guidance on which are more informative for those making test implementation decisions [24] [25] [26] . This situation is especially problematic when one considers, as noted by Schiff 2012 , it is possible "the average clinician could care less about…a new study to increase their positive predictive value" [27] . While more patient-centered research strategies have been described through controlled trials assessing outcomes of test-and-treat interventions, and through hierarchical assessments of test efficacy, such studies are less often found in the available evidence base [10, [28] [29] [30] [31] [32] .
Some of these limitations of DTA SRs may partially relate to infrequent use of an analytic framework, which provides scope and context for DTA measures, and is a recommended standard for SRs in general [33, 34] . Interpretive challenges may also arise when primary DTA studies are poorly reported or demonstrate risk of bias. Reporting standards for DTA studies are found in the Standards for Reporting of Diagnostic Accuracy, and risk of bias is identifiable through the Quality Assessment of Diagnostic Accuracy Studies risk of bias tool [35] [36] [37] [38] . For definitions and characteristics of the total testing process in general, refer to Plebani [5] .
In addition to these challenges, some SR methods [e.g. the Centers for Disease Control and Prevention, Division of Laboratory Systems (CDC DLS) Laboratory Medicine Best Practices (LMBP) method] require determination of qualitative effect size ratings (e.g. "substantial", " moderate", "minimal") as a partial determinant of the strength of body-of-evidence [33] . Table 1 details the CDC DLS LMBP method's criteria for rating the strength of a body-of-evidence, in general taking into account the number of studies (within an intervention group) with particular effect size ratings and study quality ratings.
Objective
To address these DTA SR challenges, a clinically meaningful approach was needed in order to derive a single qualitative effect size rating for each DTA study and for a body of evidence as a whole. This paper describes the approach developed, which is based on: -Location of a diagnostic accuracy study within a fourquadrant likelihood ratio scatter matrix and -Matrix quadrant demarcation derived from established likelihood ratio thresholds signifying high clinical validity.
Materials and methods
Likelihood ratios are depicted in Table 2 , and multiple resources are available to further aid in understanding and interpretation [13, 17, [39] [40] [41] [42] [43] [44] [45] . In general, clinical interpretation of likelihood ratios Interpretation cutoffs adapted from Jaeschke et al. [39] in order to convey mutually exclusive categories. Limitations of cutoffs are discussed in the Methods section.
includes use of probability thresholds, Fagan's nomogram, and Bayesian reasoning. 
Use of likelihood ratios to determine effect size rating
The American Society for Microbiology (ASM) recently completed a SR using the CDC DLS's LMBP method to derive practice recommendations for Clostridium difficile testing practices (pending publication at this time). The evidence base for this SR consisted of DTA studies, and the SR was conducted in collaboration with the CDC DLS.
DTA studies present analysis challenges not encountered when assessing other types of evidence such as randomized controlled trials and before-and-after studies [15] , and the CDC DLS LMBP SR method was not developed to optimally address some of these challenges. An important challenge is interpretation of the tradeoff between diagnostic sensitivity and specificity, particularly in the context of the LMBP method of evidence grading. Given that DTA studies report two related effects (diagnostic sensitivity and specificity), the review team determined that an approach was needed to capture (1) the trade-off between these two measures of effect, and (2) the clinical importance of this tradeoff. Lastly, an approach for deriving a single qualitative effect size rating from these measures was needed, expressible as "substantial", "moderate", or "minimal" (see Table 1 evidence rating criteria) [13] .
Approach step 1:
The solution (developed by authors MLR and JSP) was based on two diagnostic accuracy effect measures: the positive likelihood ratio (+LR) and the negative like lihood ratio (−LR). Further, the solution adopts cutoff points described in the literature as providing strong evidence of a test's ability to rule-in or rule-out a disease [8, 17, 39, 44, [46] [47] [48] [49] , and extends them into the following +LR and -LR effect pairings: -"Substantial" effect rating, if: +LR > 10 and -LR < 0.1 -"Moderate" effect rating, if: +LR > 10 and -LR > 0.1 or +LR < 10 and -LR < 0.1 -"Minimal" effect rating, if: +LR < 10 and -LR > 0.1
It is necessary to express some caveats for these likelihood ratio cutoffs. First, these cutoffs, and the post-test probabilities of disease derived by using them, are not of themselves diagnostic. Accurate diagnosis depends on integration of information arising from diagnostic processes, including history, physical findings, and results of other testing, and it depends on multi-professional efforts to overcome diagnosis "pitfalls and challenges" [27, [50] [51] [52] . Second, there is an arbitrary nature to setting cutoffs/thresholds in support of qualitative effect size judgments. Cutoffs in support of effect size interpretation, therefore, are not ironclad rules of thumb -effect size interpretation should occur in context of the practical, clinical importance for whatever is being researched [53] [54] [55] [56] . Further, while these cutoffs provide strong evidence of a test's ability to rule-in (+LR > 10) or rule-out (-LR < 0.1) a target condition, in practice this ability is dependent on a patient's pre-test probability of disease in order for a "large and…conclusive [change] from pretest to posttest probability" to be observed, as is readily demonstrated by Fagan's nomogram [17, 39, 48] . Finally, as mentioned previously, DTA values (including likelihood ratios) are not a fixed attribute of a test, but may vary according to population, setting/clinical context, or positivity threshold. Nevertheless, the approach is rooted in established cutoffs representing thresholds for "high" clinical validity in service of (1) straightforward, binary handling of data, and (2) meaningful handling of FP/FN tradeoffs often observed in DTA measures. Given broad acceptance in the literature of these likelihood cutoffs for "high" test information value, a defensible approach was established to meet a specific challenge: derive qualitative effect size measures for a DTA evidence base in a way that is amenable to the CDC DLS LMBP SR method of evidence rating. In general, approaches for simplifying information Increasing ability to assess whether a patient's probability of disease changes with a positive or negative test result *As "true positive rate" relative to "false positive rate", and as "false negative rate" relative to "true negative rate" when making judgments has demonstrated advantages, including accuracy, transparency and accessibility, when the approach is rulebased and framed to a specific context [57] . In sum, this approach allowed for meaningful derivation of effect size ratings for each DTA study, using a DTA measure that is multi-use in nature (application to "test performance, clinical utility, and decision making"), and which may overcome interpretability shortcomings associated with other DTA measures [58] [59] [60] . Finally, effect ratings derived from +LR/−LR pairings advances the notion that "test results can be valuable both when positive and negative" [61] by preserving the discrimination potential of FPs and FNs. A last note, while the mathematical ratio of +LR to −LR is commonly referred to as the diagnostic odds ratio (DOR), basing effect ratings on the DOR was determined by the review team to be an unacceptable approach. For example, values for DOR are repetitive across various pairings of +LR to −LR, as illustrated in Deeks 2001 [16] , obscuring FP and FN tradeoffs, and further challenging defensible effect rating judgments. For example, a DOR of 500 could indicate either a "substantial" or "moderate" effect if linked to this approach. It is for this reason that pairings of +LR to −LR are assessed, rather than their mathematical ratio expressed as DOR.
Approach step 2:
The second step in deriving a single qualitative effect size rating for each study was integrating these cutoffs into a four-quadrant likelihood ratio scatterplot of +LR and -LR pairings, as is further described in the next section.
Generalized approaches for determining effect size ratings
Before applying this approach, a review team in collaboration with an expert panel should identify the relative clinical importance of FPs and TPs, contextualizing the test to the relevant population and clinical setting [24, 25, 48] .
The general approach of Figure 4 may be taken when the expert panel determines the clinical importance of FPs and FNs is approximately equal, or that the test (in its intended role) should have the ability to both accurately rule-in and rule-out a target condition. From this perspective, use of point estimates [vs. use of confidence interval (CI) limits] is illustrated when judging effect size rating. However, this approach is flexible if a review team determines it is more appropriate to upgrade or downgrade an effect size rating based on whether the CI for a point estimate overlaps quadrants. For example, the effect size rating could be based on the lower end of a CI if a review team determines that aspect of an estimate is more important to communicate through effect ratings.
While the approach in Figure 4 is based on an assumption of equal weight for the clinical importance of FPs and FNs, an expert panel may determine the clinical importance of one outweighs the other. There may be scenarios, then, where what might be considered a "Moderate" effect could either be upgraded to "Substantial" or downgraded to "Minimal."
For example: -When the effects of the disease are serious, but the disease is treatable and the treatment does not cause patient harms or incur high costs. In this scenario a paired effect in the upper right quadrant of Figure 4 might be considered "Substantial" rather than "Moderate".
Scenarios involving "don't miss" medical conditions (e.g. vascular events, infections, and cancer) or "undesirable diagnostic events" [62, 63] .
Readers may also refer to Hsu et al. 2011 for additional scenarios weighing benefits of correct classification (i.e. TPs and TNs) against the harms of incorrect classifications (i.e. FPs and FNs) as may further inform tailored use of these likelihood scatter matrices [24] . Lastly, readers may also consider the literature on "misdiagnosis" (i.e. wrong diagnosis), "missed diagnosis", or "delayed diagnosis" [64] [65] [66] [67] . Therefore, as an alternative to the approach illustrated in Figure 4 , one of the following perspectives may be emphasized: -Rule-in a target condition (or when the clinical importance of FP results outweighs that of FN results) or -Rule-out a target condition (or when the clinical importance of FN results outweighs that of FP results). Figure 5 depicts this alternative perspective when using the +LR/−LR scatter matrix to derive effect size ratings. In this case, the figure also depicts how interpretation of effect size may be affected by whether a point's CIs cross quadrants, with "moderate" effects occurring when the CI crosses the horizontal line (left-hand Figure) or the vertical line (right-hand Figure) .
Results

Likelihood ratio scatter matrix in the ASM-CDC DLS SR
There are two considerations when rating effect sizes for DTA statistics: (1) identifying an overall index of sample size as relates to the tradeoff between sensitivity and specificity; and (2) weighing their relative clinical importance. To create an overall index of effect, the likelihood ratio scatter matrix was created using the midas command in Stata 15 (Stata Corp., College Station, TX, USA). These scatterplot matrices can be created in any standard statistical package, though the midas procedure in Stata provides the benefit of computing these via a subroutine of the more general diagnostic meta-analysis procedure. Figure 6 illustrates the likelihood ratio scatter matrix used as a practical tool to rate effect sizes for the SR on C. difficile testing approaches. When paired likelihood ratios were within areas indicating high clinical validity (+LR > 10 and -LR < 0.1), the review team in collaboration with the project's expert panel described this as a "Substantial" effect, especially if the CIs of the estimate (as represented by the crosshairs on the summary diamond) did not cross into other quadrants. When only one of the Effect size rating for studies whose +LR/-LR pairings cross these quadrants = "substantial" Effect size rating for studies whose +LR/-LR pairings cross these quadrants = "substantial" Effect size rating for studies whose +LR/-LR pairings cross these quadrants = "minimal" Effect size rating for studies whose +LR/-LR pairings cross these quadrants = "minimal" Effect size rating for studies whose +LR/-LR pairings cross these quadrants = "moderate" Effect size rating for studies whose +LR/-LR pairings and CIs cross these quadrants = "moderate" likelihood ratios was within the areas used to indicate high clinical validity, it was considered a "Moderate" effect. Table 3 illustrates how qualitative effect size ratings subsequently informed the final level of qualitative synthesis in the ASM-CDC DLS SR: rating of overall strength of body-of-evidence using CDC DLS LMBP criteria ( Table 1) . Strength of body-of-evidence ratings were then used to inform practice recommendations, with three C. difficile test practices achieving a "recommended" categorization as shown in Table 3 . This table provides counts for only the highest rated pairings of quality-to-effect for each test practice category. A list of quality ratings and effect size ratings for all studies in the SR is available from the authors upon request, as are details on specific testing practices assessed.
Discussion
Additional implication of this effect rating approach Additional methods of grading evidence
Other methods for grading the strength of evidence, such the Grading of Recommendations Assessment, Development and Evaluation (GRADE) [68] , may benefit from this effect size rating approach. As when applying the CDC DLS LMBP method to a DTA evidence base, challenges in applying GRADE have been described [24, 25, 69] . Some of these challenges in GRADE have been (in part) addressed by considering DTA a surrogate (intermediate) patient outcome, to the extent that rates of TP, FP, TN, and FN can be inferably linked to patient management or patient health consequences [23, 25, 69, 70] . However, expressing "magnitude of effect" -one of the GRADE criteria for assessing the strength of evidence -for a DTA evidence base appears to remain a challenge.
In GRADE, "magnitude of effect" is a criterion that can upgrade the strength of evidence. While Gopalakrishna et al. 2014 described important challenges in applying three of the GRADE strength of evidence criteria (inconsistency, imprecision, and publication bias), there is no clear solution provided for assessing "magnitude of effect" for DTA. Yet, several GRADE papers, including Gopalakrishna et al. 2014 , recommend that (1) the differential patient consequences of TPs, FP, TNs, and FNs be considered when making recommendations from a DTA evidence base, and that (2) these differential consequences should inform emphasis of particular DTA measures [24, 25, 69] . On this last point, however, little detailed guidance is provided.
We suggest these a priori considerations can be expressed through an analytic framework for DTA SRs, which should depict inferable (in the absence of direct evidence) clinical outcome types. Clinical outcomes that can be linked to laboratory testing have been described in the literature [71] [72] [73] . Further, by appropriating the effect rating approach described here, patient-important consequences of TPs, FPs, TNs, and FNs can be preserved through pairings of +LR/−LN in a way that (1) is readily visualized for "magnitude of effect" assessment, and that (2) promotes transparent, defensible, and reproducible judgments on effect rating toward grading the strength of a body of evidence. In this way DTA SR "judgments on which would be the more critical accuracy measures to focus" [69] could be addressed in a straightforward, intuitive way that is comparable across DTA SRs.
In sum, this +LR/−LR effect rating approach provides a defensible means of deriving effect ratings, as can then inform potential upgrading of strength of evidence when using the GRADE method [74, 75] .
For diagnostic quality and safety measures
Diagnostic error has been defined as the "failure to (a) establish an accurate and timely explanation of the patient's health problem(s), or (b) communicate that explanation to the patient" [76] . Identifying meaningful measures of diagnostic quality and safety, however, is a noted challenge [50, [76] [77] [78] . While "diagnostic accuracy" in this context signifies more than simply "DTA" (or test clinical validity) [4, 50, 76] , +LR/−LR pairings represent an aspect of diagnostic information quality and can aid test interpretation, although (of themselves) are not necessarily a suitable direct measure of diagnostic quality and safety. In this way, +LR/−LR scatterplot matrix pairings may inform the "Diagnostic Process" domain of quality and safety measures described in the 2017 National Quality Forum (NQF) report Improving Diagnostic Quality and Safety. DTA can be equated with a component of diagnostic accuracy identified in the NQF report as "measurement of initial diagnostic accuracy" or "accuracy of initial diagnosis" [50] . In this context, +LR/−LR scatterplot matrix pairings signal a test's (or a combination of tests) ability to correctly or incorrectly classify patients in relation to a diagnosis, in a way that is straightforward, visual, and clinically meaningful. Further, +LR/−LR pairings may provide an additional means to express whether "diagnostic tests have adequate analytical and clinical validity [as is] critical to preventing diagnostic errors" [76] .
Limitations
While benefiting transparent effect rating judgments, any approach that simplifies findings risks information loss. For example, this approach does not contain information as to resource utilization (e.g. costs), patient preferences, or the indirectness of evidence to patient outcomes. Readers are further cautioned that a diagnostic test is not an isolated element of the patient diagnostic process; however, a test provides information, the quality of which can be assessed toward test utility and patient-related outcomes. Additionally, the strength of this approach may be diminished if DTA for an index test is established in relation to an imperfect reference standard, although this concern was not formally assessed [79, 80] .
Finally, use of probabilistic tools (e.g. likelihood ratios, Bayesian reasoning) and "statistical numeracy" has been shown to challenge health care professionals when interpreting diagnostic information [58, 60, [81] [82] [83] . Yet, this approach to interpreting DTA measures may be relevant to interventions to improve clinical insights from diagnostic reasoning [84] , especially in cases where laboratories implement recommendations to provide likelihood ratios in results reporting [59] .
Conclusions
Findings of DTA SRs should be interpreted in relation to intended clinical use in support of diagnostic quality and safety. The approach described in this paper facilitates meaningful interpretation of results, as well as determination of qualitative effect size ratings. In this way, +LR/−LR scatterplot matrix pairings are answerable to the call to "move beyond summary measures and ask how a new diagnostic test reclassifies patients" [20] by facilitating ratings of effect linked to clinical practice. 
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